1. Apoptosis
  2. Apoptosis
  3. Minnelide

Minnelide 

Cat. No.: HY-124584
Handling Instructions

Minnelide is a prodrug of triptolide that shows potent antitumor activity in a number of tumor types, particularly in pancreatic cancer. Minnelide causes apoptotic.

For research use only. We do not sell to patients.

Minnelide Chemical Structure

Minnelide Chemical Structure

CAS No. : 1254702-87-8

Size Stock
1 mg   Get quote  
5 mg   Get quote  

* Please select Quantity before adding items.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Minnelide is a prodrug of triptolide that shows potent antitumor activity in a number of tumor types, particularly in pancreatic cancer. Minnelide causes apoptotic[1].

In Vitro

Minnelide (0-200 nM; 48 hours) shows significantly decreased cell viability in pancreatic cancer cell lines after treatment in the presence, but not in the absence, of phosphatase[2].

Cell Viability Assay[2]

Cell Line: Pancreatic cancer cell line: S2-013, MIA PaCa-2, S2-VP10, and Panc-1 cells
Concentration: 0.100 nM, 200 nM
Incubation Time: 48 hours
Result: Decreased cell viability of in vitro.
In Vivo

Minnelide (injection intraperitoneally; 0.1-0.6 mg/kg; once daily or twice daily) leads to a marked decrease in tumor weight and volume at the end of treatment and increases survival in orthotopic model of pancreatic cancer with MIA PaCa-2–derived human pancreatic tumors[2].
Minnelide (injection intraperitoneally; 0.42 mg/kg; once daily; 28 days) prevents locoregional spread and leads to a decrease in average tumor weight in a xenograft model of pancreatic cancer with metastatic S2-013 cells[2].
Minnelide (injection intraperitoneally; 0.42 mg/kg, 0.21 mg/kg; once daily) causes tumor regression and tumors from Minnelide-treated animals showed fibrosis and the presence of pyknotic nuclei in human pancreatic cancer xenografts in SCID mice[2].

Animal Model: Orthotopic model of pancreatic cancer with MIA PaCa 2-derived human pancreatic tumors in athymic nude mice[2]
Dosage: 0.1-0.6 mg/kg
Administration: Injection intraperitoneally; 0.1-0.6 mg/kg; once daily or twice daily
Result: Prevented pancreatic tumor growth in vivo.
Animal Model: Xenograft model of pancreatic cancer with metastatic S2-013 cell line in athymic nude mice[2]
Dosage: 0.42 mg/kg
Administration: Injection intraperitoneally; 0.42 mg/kg; once daily
Result: Prevented extensive spread from the primary site of injection.
Animal Model: Human pancreatic cancer xenografts in SCID mice[2]
Dosage: 0.21 mg/kg, 0.42 mg/kg
Administration: Injection intraperitoneally; 0.42 mg/kg; once daily
Result: Reduced tumor burden in human xenografts from patients.
Molecular Weight

514.37

Formula

C₂₁H₂₅Na₂O₁₀P

CAS No.

1254702-87-8

SMILES
Shipping

Room temperature in continental US; may vary elsewhere

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Minnelide
Cat. No.:
HY-124584
Quantity: